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Summary
Recent studies provide evidence of correlations of DNA methy-
lation and expression of protein-coding genes with human aging.
The relations of microRNA expression with age and age-related
clinical outcomes have not been characterized thoroughly. We
explored associations of age with whole-blood microRNA expres-
sion in 5221 adults and identified 127 microRNAs that were
differentially expressed by age at P < 3.3 3 104 (Bonferroni-
corrected). Most microRNAs were underexpressed in older indi-
viduals. Integrative analysis of microRNA and mRNA expression
revealed changes in age-associated mRNA expression possibly
driven by age-associated microRNAs in pathways that involve
RNA processing, translation, and immune function. We fitted a
linear model to predict ‘microRNA age’ that incorporated expres-
sion levels of 80 microRNAs. MicroRNA age correlated modestly
with predicted age from DNA methylation (r = 0.3) and mRNA
expression (r = 0.2), suggesting that microRNA age may comple-
ment mRNA and epigenetic age prediction models. We used the
difference between microRNA age and chronological age as a
biomarker of accelerated aging (Dage) and found that Dage was
associated with all-cause mortality (hazards ratio 1.1 per year
difference, P = 4.2 3 105 adjusted for sex and chronological
age). Additionally, Dage was associated with coronary heart
disease, hypertension, blood pressure, and glucose levels. In
conclusion, we constructed a microRNA age prediction model
based on whole-blood microRNA expression profiling. Age-
associated microRNAs and their targets have potential utility to
detect accelerated aging and to predict risks for age-related
diseases.
Key words: aging; cardiometabolic traits; methylation;
microRNA; mortality; mRNA.
Introduction
Human aging is a complex process that has been linked to dysregulation
of numerous cellular and molecular processes, including shortened
telomere length (Harley et al., 1990), altered DNA damage response
(Moskalev et al., 2013), loss of protein homeostasis (Tomaru et al.,
2012), cellular senescence (Childs et al., 2015), and mitochondrial
dysfunction (Green et al., 2011). Those cellular and molecular processes
can lead to a variety of diseases including cancer, cardiovascular disease,
and neurological disease, as well as an increased risk of mortality
(Fontana et al., 2010; Lopez-Otın et al., 2013).
Recent studies have revealed that human aging can be characterized
by changing patterns of DNA methylation (Hannum et al., 2013;
Horvath, 2013) and expression of protein-coding genes (Peters et al.,
2015). A growing body of research suggests that aging is associated
with changes in DNA methylation both genome-wide and at specific C-G
dinucleotide (CpG) loci. Two recent studies developed age predictors
based on the methylation state of CpGs in whole blood and other tissues
(Hannum et al., 2013; Horvath, 2013). The resultant DNA methylation-
based predicted age (i.e., DNAm age) was associated with chronological
age in several independent studies. The difference between DNAm age
and chronological age (i.e., DNAm Dage) has been proposed as an index
of accelerated aging and was reported to be associated with all-cause
mortality and several coronary heart disease risk factors (Marioni et al.,
2015; Christiansen et al., 2016; Horvath et al., 2016).
At the mRNA level, a recent meta-analysis of whole-blood gene
expression in ~15 000 individuals identified 1497 mRNAs that are
differentially expressed in relation to age (Peters et al., 2015). An age
predictor based on mRNA expression (i.e., mRNA age) highlighted genes
involved in mitochondrial, metabolic, and immune function-related
pathways as key components of aging processes. The difference
between mRNA age and chronological age (i.e., mRNA Dage) correlated
with many metabolic risk factors including blood pressure, total
cholesterol levels, fasting glucose, and body mass index (BMI) (Peters
et al., 2015).
MicroRNAs (miRNAs) are a class of small noncoding RNAs that
downregulate protein-coding genes by either cleaving target mRNAs or
suppressing translation of mRNAs into proteins (Lee & Ambros, 2001;
Lee et al., 2004; Cordes & Srivastava, 2009). Research in a
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Caenorhabditis elegans model system revealed changes in miRNA
expression in relation to lifespan and longevity (Boehm & Slack, 2005;
Iba~nez-Ventoso et al., 2006; Pincus et al., 2011). In humans, highly
specific miRNA expression patterns are correlated with many age-related
diseases including cardiovascular disease (Small & Olson, 2011; Huan
et al., 2015c) and cancer (Lu et al., 2005; Hayes et al., 2014). Recent
studies have examined differentially expressed miRNAs in relation to age
in whole blood (ElSharawy et al., 2012), peripheral blood mononuclear
cells (PBMC) (Noren Hooten et al., 2010), and serum (Noren Hooten
et al., 2013; Zhang et al., 2014). These studies, however, were based on
small sample sizes, limiting the power to investigate age-related changes
in miRNA expression. We hypothesized, a priori, that it would be possible
to create a miRNA signature of age that is predictive of chronological age
and that age prediction based on miRNA expression is biologically
meaningful and can be used as a biomarker of risk for age-related
outcomes including all-cause mortality.
In a previous study, we measured miRNA expression in whole blood
from more than 5000 Framingham Heart Study (FHS) participants. We
investigated the heritability of miRNA expression and performed a
genome-wide association study (GWAS) of miRNA expression to identify
miR-eQTLs (Huan et al., 2015b). Our results showed that miRNAs are
under strong genetic control. In the present study, we further investi-
gated whole-blood miRNA expression in relation to chronological age in
FHS participants. Fig. S1 shows the overall study design. We identified
127 miRNAs that were differentially expressed in relation to chronolog-
ical age, and performed internal validation by splitting the samples 1:1
into two independent sample sets. An integrative miRNA–mRNA
coexpression analysis and miRNA target prediction revealed many age-
related pathways underlying age-associated molecular changes. We also
defined and evaluated an age predictor based on miRNA expression
levels (i.e., miRNA age). Our results indicate that the difference between
miRNA age and chronological age (i.e., miRNA Dage) is associated with
multiple age-related clinical traits including all-cause mortality, coronary
heart disease (CHD), hypertension, blood pressure, and glucose levels. In
addition, we compared miRNA age with DNAm age and mRNA age in
FHS participants.
Results
Study population
Table 1 shows the characteristics of the 5221 FHS participants in this study
(2295 participants from the FHS offspring cohort and 2926 participants
from the FHS third-generation cohort). At the time of measured sample
collection for miRNA isolation, the FHS Offspring cohort was on average
20 years older than the Third Generation cohort (mean age 66 vs.
46 years). As expected, given the age differences between cohorts, the
Offspring cohort had a higher prevalence of cardiovascular disease risk
factors. In addition, during 6 years of follow-up, incident deaths occurred
more commonly in the Offspring cohort (257 vs. 12).
We split the 5221 FHS samples 1:1 by pedigrees into independent
discovery and replication sets (see Methods). The mean age was 54.9 in
the discovery set and 55.4 in the replication set (P = 0.21). Other clinical
factors did not differ between the discovery and replication sets.
Identification of differentially expressed miRNAs in relation
to chronological age
We identified 127 miRNAs that were differentially expressed in relation to
chronological age at P < 3.3 9 104 (Bonferroni-corrected, 0.05/150).
The incremental proportion of interindividual difference in age explained
by the 127 differentially expressed miRNAs ranged from partial r2 of
0.002–0.15. Table 2 provides results for the top 25 miRNAs, and
Table S1 provides the full list. Of the 127 age-associated miRNAs, 103
(81%) miRNAs were negatively correlated with age and 24 (19%)
miRNAs were positively correlated (Fig. 1). Age-related miRNA expres-
sion studies in whole blood (ElSharawy et al., 2012), PBMCs (Noren
Hooten et al., 2010), and serum (Noren Hooten et al., 2013; Zhang
et al., 2014) have similarly reported that the majority of age-related
miRNAs show decreased expression in older individuals.
The age associations of miRNAs in the discovery and replication sets
were highly consistent with Pearson’s correlations (r) of beta values
(effect size) of > 0.99 and of log10-transformed P values of 0.97
(Fig. S2). Ninety-one percentage of differentially expressed miRNAs in
relation to age in the discovery set (at P < 3.3 9 104) replicated in the
replication set (at P < 3.3 9 104). The validation results suggest that
age-associated miRNA expression signatures are robust and highly
replicable.
In conducting a sensitivity analysis, we identified differentially
expressed miRNAs in relation to age separately in the FHS Offspring
cohort and FHS Third Generation cohort (Tables S2 and S3). At
P < 3.3 9 104, there were 32 age-associated miRNAs identified in
the FHS Offspring cohort and 57 in the larger FHS Third Generation
cohort. A total of 23 miRNAs overlapped between cohorts. The Pearson
correlation of beta values for all 150 measured miRNAs between cohorts
was 0.67 (Fig. S3). These results suggest that age-associated miRNA
expression differs slightly across age groups.
miRNA age prediction
We used elastic net regression (Friedman et al., 2010) to select miRNAs
for building an age prediction model using 10-fold cross-validation. To
Table 1 Framingham heart study offspring and third generation cohort study
participant characteristics
Phenotypes/Covariates
Offspring
cohort
N = 2295
Third
generation
cohort
N = 2926
Male (%) 44 46
Age (years), mean (SD) 66 (9) 46 (9)
Body mass index (kg m2), mean (SD) 28.3 (5.4) 28.0 (5.9)
Systolic blood pressure (mm Hg), mean (SD) 129 (17) 116 (14)
Diastolic blood pressure (mm Hg), mean (SD) 73 (10) 74 (9)
Serum glucose (mg dL1), mean (SD) 107 (23) 96 (18)
High-density lipoprotein (mg dL1), mean (SD) 59 (18) 60 (18)
Total cholesterol (mg dL1), mean (SD) 186 (37) 187 (35)
Triglycerides (mg dL1), mean (SD) 118 (70) 113 (79)
Current smokers, n (%) 147 (6) 341 (12)
Hypertension, n (%) 1449 (63) 719 (25)
Hypertension, no hypertensive treatment, n (%) 209 (9) 170 (6)
Prevalent diabetes mellitus, n (%) 317 (14) 156 (5)
Prevalent diabetes mellitus, no diabetes
treatment, n (%)
108 (5) 56 (2)
Prevalent coronary heart disease, n (%) 219 (10) 31 (1)
Deaths, n (%) 257 (11) 12 (0)
Hypertensive treatment, n (%) 1196 (52) 544 (19)
Diabetes treatment, n (%) 209 (9) 103 (4)
Lipids treatment, n (%) 951 (41) 453 (15)
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ensure unbiased validation, the age prediction model was trained only in
the discovery sample set. Table S4 reports the results of the prediction
model that included 80 miRNAs. Seventy-two of the 80 miRNAs in the
prediction model showed differential expression in relation to age at
P < 3.3 9 104.
The correlation between miRNA predicted age (miRNA age) and
chronological age was significant in the discovery (Pearson’s correlation
r = 0.70; P < 1 9 10320) and replication sets (r = 0.65;
P = 2.7 9 10311) (Fig. 2). We hypothesized that the difference
between miRNA age and chronological age (miRNA Dage) is an index
of ‘biological’ aging, with a positive Dage indicating accelerated aging,
and a negative Dage reflecting slower aging in comparison with
chronological age. miRNA Dage was not associated with miRNA age
(Fig. S4).
In conducting a sensitivity analysis to account for cohort effects, we
used the same method to train a miRNA age prediction model in the FHS
Offspring and Third Generation cohorts separately (Fig. S5). When the
two cohorts were used as separate discovery-replication sets, the
correlation between miRNA age and chronological age was stronger in
the Offspring cohort (Pearson’s correlation r = 0.50 and
P = 1.2 9 1073) than in FHS Third Generation cohort (Pearson’s
correlation r = 0.36 and P = 2.7 9 1045). The different correlation
between miRNA age and chronological age in cohort-specific analysis
could be explained by differences in mean age, age range, and
unmeasured technical factors.
Heritability of miRNA Dage
The estimate of heritability of miRNA Dage (h2miRDage) was 0.38. To
determine whether any specific genetic variants correlate with miRNA
Dage, we performed a genome-wide association study of miRNA Dage
using all available FHS samples (see Fig. S6 for the Manhattan plot).
There were no SNPs associated with miRNA Dage at P < 5 9 108.
We previously reported that miRNA expression levels are highly
heritable, and identified 5269 miRNA expression-associated SNPs for 76
miRNAs within +/- 1 MB of the associated SNP (i.e., cis-miR-eSNPs). We
further explored whether miRNA Dage is linked to cis-miR-eSNPs. No cis-
miR-eSNPs were associated with miRNA Dage at P < 1 9 105.
Influence of blood cell types on miRNA age
We compared the differentially expressed miRNAs in relation to age both
with and without adjustment of blood cell types. As shown in Fig. S7,
the Pearson correlation coefficients of beta values with vs. without
adjustment for blood cell types were > 0.99, and for log10-transformed
P values, it was > 0.99. In addition, 122 of the 127 age-associated
miRNAs (96%) remained significant after adjusting for blood cell types,
indicating that adjusting for blood cell type proportions had little effect
on our results.
In conducting a sensitivity analysis adjusting for white blood cell
counts, the miRNA age predictor exhibited a weaker but still high
correlation with chronological age (r = 0.61) in the replication set. Cell
type effects explained a proportion of age variability, which may have
resulted in the weaker correlation observed between miRNA age and
chronological age after adjusting for cell types.
miRNA Dage is predictive of all-cause mortality and
correlated with many metabolic traits
The association of miRNA Dage with all-cause mortality was tested in
FHS Offspring participants (there were too few deaths in the Third
Generation cohort for meaningful analysis). We found that miRNA Dage
was associated with mortality with a hazards ratio (HR) of 1.10 (95% CI
1.05–1.14; P = 4.2 9 105) per year of miRNA Dage after adjustment
for chronological age and sex. Kaplan–Meier survival curves for miRNA
Dage tertiles are presented in Fig. 3. The plot illustrates higher mortality
rates for those with higher Dage. Sensitivity analyses were performed to
Table 2 Top 25 differentially expressed miRNAs in relation to chronological age
miRNA Estimated Beta† SE R-squared P-Value
miR-99b-5p 0.07 0.002 0.15 1.16E-286
miR-130b-5p 0.06 0.002 0.11 3.04E-227
miR-505-5p 0.06 0.002 0.12 3.04E-226
miR-425-3p 0.08 0.002 0.10 8.58E-203
miR-144-5p 0.11 0.004 0.09 1.55E-165
miR-182-5p 0.10 0.003 0.08 7.29E-157
miR-1275 0.08 0.003 0.08 5.40E-149
miR-601 0.09 0.003 0.08 4.48E-146
miR-206 0.07 0.003 0.08 4.48E-139
miR-30a-5p 0.03 0.001 0.08 9.07E-132
miR-218-5p 0.07 0.003 0.07 4.94E-130
miR-30d-5p 0.04 0.002 0.07 9.10E-127
miR-502-3p 0.05 0.002 0.06 5.28E-116
miR-28-3p 0.08 0.003 0.06 7.96E-114
miR-197-3p 0.04 0.002 0.06 3.69E-111
miR-320b 0.04 0.002 0.07 4.77E-110
miR-576-3p 0.06 0.002 0.06 2.58E-105
miR-181a-5p 0.06 0.003 0.05 2.61E-87
miR-18a-5p 0.05 0.003 0.05 2.93E-86
miR-223-5p 0.05 0.002 0.05 6.86E-86
miR-339-5p 0.04 0.002 0.05 1.65E-85
miR-24-3p 0.03 0.001 0.05 2.08E-84
miR-22-3p 0.06 0.003 0.05 2.14E-84
miR-345-5p 0.04 0.002 0.05 1.66E-82
miR-302c-3p 0.08 0.004 0.05 2.83E-82
†Higher Ct values indicate lower miRNA expression levels. Therefore, positive beta
values indicate negative associations between miRNA expression and age.
Fig. 1 Volcano plot of differentially expressed miRNAs in relation to chronological
age. Higher Ct values indicate lower miRNA expression levels. Therefore, positive
beta values indicate negative associations between miRNA expression and age.
microRNA expression age of blood, T. Huan et al. 3
ª 2017 The Authors. Aging Cell published by the Anatomical Society and John Wiley & Sons Ltd.
control for additional potential confounders (cigarette smoking, HDL
cholesterol, total cholesterol, triglycerides, systolic and diastolic blood
pressure, fasting blood glucose, BMI, lipid treatment, diabetes treat-
ment, hypertension treatment, prevalent cancer, prevalent CHD, and
prevalent diabetes). The fully adjusted HR was 1.15 (95% CI 1.08–1.22;
P = 2.5 9 105).
The association of miRNA Dage with prevalent CHD was tested in all
available individuals (a total of 250 prevalent CHD cases). The associ-
ations of miRNA Dage with prevalent diabetes and hypertension were
tested in individuals who were not receiving medications to treat
diabetes and hypertension (including 164 diabetes cases and 379
hypertension cases), respectively. We found miRNA Dage to be positively
associated with CHD (P = 3.8 9 1017) and hypertension (P = 0.002),
after adjustment for chronological age, sex, and BMI (Table 3).
We also tested the associations of miRNA Dage with multiple
cardiometabolic traits using all available FHS participants who were not
receiving medications to treat hypertension, dyslipidemia, or diabetes
(N = 2993). These analyses revealed miRNA Dage to be positively
associated with systolic blood pressure, diastolic blood pressure, and
fasting glucose levels at P < 0.005 (Bonferroni-corrected, 0.05/10 tests)
after adjusting for age, sex, and BMI (Table 3).
miRNA–mRNA coexpression, miRNA targets, and pathway
analyses
To better understand how miRNAs might contribute to aging processes,
we further tested whether expression levels of age-associated mRNA
transcripts are mirrored by differential expression of age-associated
miRNAs. For this purpose, we analyzed miRNA–mRNA coexpression in
the same set of FHS individuals (n = 5012) in whom miRNA and mRNA
expression data were both available. For the 127 age-associated
miRNAs, the coexpression analysis identified 4682 mRNAs that were
highly coexpressed with the 123 age-related miRNAs at FDR < 0.05,
including 24 310 miRNA–mRNA coexpression pairs. Of the 4682 mRNAs
that were coexpressed with age-associated miRNAs, 551 mRNAs were
previously reported to be age-associated (Peters et al., 2015); the total
number of reported age-associated mRNAs in that study was 1497.
Comparison of the two ratios (4682/17 318 measured mRNAs and 551/
1497) yielded P < 1 9 1016 (by the hypergeometric test), suggesting
that age-associated differences in miRNA expression are indicative of
age-associated changes in their coexpressed mRNAs. Gene ontology
enrichment analysis (Table S5) showed that the coexpressed mRNAs are
enriched for translation (P = 3.3 9 107), immune response
(P = 9.4 9 107), and RNA processing (P = 1.7 9 105).
Among the miRNA–mRNA coexpression pairs, TargetScan v7.0 (Lewis
et al., 2005; Agarwal et al., 2015) predicted 3552 of the 4682 mRNAs
to be potential corresponding targets for the coexpressed age-associated
miRNAs, including 406 of the 551 age-associated mRNAs (~74%).
Details of miRNAs and their coexpressed/predicted target mRNAs
involved in each GO category are provided in Table S6.
Comparing miRNA age with mRNA age and DNAm age
In our previous studies, we used mRNA expression and DNA methylation
data to predict age (i.e., mRNA age and DNAm age) in FHS Offspring
Fig. 2 miRNA age vs. chronological age. (A) In the discovery set; (B) in the replication set.
Fig. 3 Survival probability by tertiles of miRNA Dage.
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participants (Marioni et al., 2015; Peters et al., 2015). In order to
compare miRNA age with mRNA age and DNAm age, we used miRNA
age calculated only in the FHS Offspring cohort. The Pearson correlation
(r) of chronological age with miRNA age in the FHS Offspring cohort was
0.50 (P = 1.2 9 1073). The r values of chronological age with mRNA
age and DNAm age were 0.56 and 0.73, respectively. As shown in
Fig. 4, miRNA age was positively correlated with mRNA age and DNAm
age, with r values of 0.20 and 0.34, respectively. DNAm age and mRNA
age were also positively correlated (r = 0.43).
When mRNA age and DNAm age were both regressed on chrono-
logical age, the r2 was 0.57. Regressing miRNA age, mRNA age, and
DNAm age on chronological age yielded an r2 of 0.63. Using data from
individuals whose miRNA and mRNA data were both available
(N = 2784), we further tested the associations of miRNA Dage with
cardiometabolic traits adjusting for mRNA Dage, as shown in Table S7.
The results did not change appreciably when adding mRNA Dage in the
model. The miRNA Dage remained associated with CHD, hypertension,
BP, and glucose. We did not include DNAm Dage in the model, because
DNA methylation data were available in a smaller number of eligible
individuals.
Discussion
We systematically assessed age-associated differences in whole-blood
miRNA expression levels and developed a miRNA age predictor. We
calculated the difference between miRNA predicted age and chrono-
logical age to generate Dage, which we put forth as an indicator of an
individual’s rate of biological aging. We found Dage to be associated
with risk for all-cause mortality and with prevalent CHD, hypertension,
and glucose levels.
In comparison with previous age-related miRNA expression studies
(Noren Hooten et al., 2010, 2013; ElSharawy et al., 2012; Zhang et al.,
2014), our study included > 25 times as many participants (N = 5221 vs
N < 200) and a wide age range (24–92 years). As such, our study was
well powered to investigate differential levels of miRNA expression in
relation to age. Among the 150 whole-blood miRNAs available for
analysis in this study, we identified 127 miRNAs that were differentially
expressed in relation to age at P < 0.05/150. The differential expression
patterns of miRNAs were highly consistent between separate discovery
and replication sample sets. The effect sizes (r2) of individual differential
miRNA expression with age were small, ranging from 0.05–0.15
(Table 2), limiting the use of single miRNAs as clinical biomarkers of
age. The small effect sizes required a large sample size to identify a-
multiple miRNA age-related biomarker.
By comparing the FHS Offspring and Third Generation cohorts, as
shown in Fig. S3, the estimated beta values for 150 measured miRNAs in
relation with age are consistent between cohorts. All 23 significant age-
associated miRNAs that overlapped between the two cohorts showed a
concordant direction of effects. However, there were more than 50
miRNAs that were significant in the overall sample set, but not in either
Table 3 Associations of miRNA Dage with
prevalent CHD, diabetes, hypertension, and
cardiometabolic traits
Trait/Disease
Chronological age miRNA Dage
Estimated Beta SE T-Value P-Value Estimated Beta SE T-Value P-Value*
CHD 15.28 0.84 18.20 8.72E-72 5.42 0.64 8.45 3.76E-17
Hypertension 9.45 0.64 14.84 2.76E-48 1.62 0.53 3.05 2.34E-03
Diabetes 8.42 1.05 8.02 1.28E-15 1.01 0.77 1.30 1.94E-01
Total cholesterol 0.82 0.05 15.84 3.81E-54 0.05 0.07 0.82 4.14E-01
High-density lipoprotein 0.07 0.02 2.73 6.34E-03 0.06 0.03 2.00 4.61E-02
Triglycerides 0.26 0.10 2.51 1.21E-02 0.18 0.13 1.36 1.73E-01
Systolic blood pressure 0.55 0.02 26.27 5.09E-136 0.10 0.03 3.78 1.58E-04
Diastolic blood pressure 0.08 0.01 6.00 2.24E-09 0.06 0.02 3.65 2.67E-04
Glucose 0.31 0.02 15.81 5.78E-54 0.07 0.02 2.86 4.30E-03
Body mass index 0.004 0.01 0.52 6.01E-01 0.002 0.01 0.24 8.11E-01
*The P-value threshold for significance for miRNA Dage vs. traits analyses (P < 0.005) was determined by the Bonferroni
method (0.05/10). Significant P-values are shown in boldface.
Fig. 4 Comparison of miRNA Dage, mRNA age, and DNAm age. (A) miRNA age vs. DNAm age; (B) miRNA age vs. mRNA age; (C) mRNA age vs. DNAm age.
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cohort. Because the cohort-specific analysis reduced the available sample
size by about half, the differences by cohort may have arisen from
reduced power. Another possible reason for differences by cohort is that
the correlation of miRNA expression with age may differ in the younger
and older cohorts, which differed in age by an average of 20 years
(Noren Hooten et al. 2013). However, we cannot exclude undetected
technical factors contributing to differences between the cohorts.
Many of our identified miRNAs were previously shown to be
differentially expressed in relation to age in whole blood (ElSharawy
et al., 2012), PBMCs (Noren Hooten et al., 2010), and serum (Noren
Hooten et al., 2013; Zhang et al., 2014; Smith-Vikos et al., 2016). For
example, miR-130b-5p (the second most significant miRNA in our study)
was previously reported to be negatively associated with age in serum
(Zhang et al., 2014). In addition, miR-340-3p was reported to be
significantly downregulated in long-lived individuals vs. short-lived
individuals (Smith-Vikos et al., 2016). In mouse studies, miR-130b-5p
was shown to regulate cholesterol and triglyceride homeostasis
(Wagschal et al., 2015). One of our top 25 miRNAs, miR-24, was
reported to be negatively correlated with age in whole blood (ElSharawy
et al., 2012) and PBMCs (Noren Hooten et al., 2010). One study found
that increased expression of miR-24 in T-cell lines downregulated the
expression of histone H2A family member X, which plays a key role in
DNA damage response (Brunner et al., 2012). We also found that most
of the age-associated miRNAs are downregulated in older individuals,
consistent with previous findings.
miRNAs play a pivotal role in post-transcriptional regulation of
protein-coding genes. Therefore, we hypothesized that age-associated
mRNAs might be regulated by age-associated miRNAs. Our miRNA–
mRNA coexpression and target prediction analysis revealed that the
coexpressed/targeted mRNAs for the identified age-associated miRNAs
were enriched for previously reported age-associated mRNAs (enrich-
ment P < 1.0 9 1016) (Peters et al., 2015). This result suggests that
age-associated changes in miRNA expression levels may alter the
expression of their targeted protein-coding genes, which play vital roles
in aging processes. GO analysis results were consistent with effects on
known aging mechanisms including regulation of transcription, transla-
tion, and immune response.
The regulation of transcription and translation of protein-coding
genes is essential to aging processes. In C. elegans studies, reducing the
levels of key proteins involved in translation, such as ribosomal proteins,
ribosomal-protein S6 kinase, and translation initiation factors, increased
the lifespan of C. elegans (Hansen et al., 2007; Pan et al., 2007).
Ribosomal-protein S6 kinase also regulates lifespan in mammalian
models (Selman et al., 2009). miRNAs in Drosophila have been shown to
block the eIF4F translation initiation complex assembly, thereby inhibit-
ing overall translation of protein-coding genes (Fukaya et al., 2014).
Similarly, a recent study reported that miR-139 represses the translation
initiation factor EIF4G2 and thereby reduces overall protein synthesis
(Emmrich et al., 2016). Our results found that many miRNAs (e.g., miR-
139 and miR-140) were coexpressed with and targeted many ribosomal
genes (e.g., RPL11 and RPL30) as well as translation initiation and
elongation genes (e.g., EEF2 and EIF4B) (Table S6). Our results call for
further functional studies to explore the specific mechanisms by which
age-associated miRNAs exert their effects on aging and age-related
diseases through regulation of key transcription and translation genes.
Many miRNAs have been found to be involved in immune pathways.
For example, previous studies showed that miR-181a regulates local
immune balance (Liu et al., 2012) and T-cell sensitivity (Li et al., 2007),
although its mechanistic action remains unclear. We found that miR-
181a-3p was coexpressed with and predicted to target three immune
response genes, namely CXCL16, RAB27A, and SPON2. RAB27A is also
involved in the T-cell activation pathway. Other identified miRNAs such
as miR-193b-3p target immune function-related genes, including CTSW,
ETS1, FAIM3, ICOS, TGFBR3, DPP4, and KIF13B. Similarly, miR-31-5p
targets CD27, FASLG, INPP5D, TCF7, TGFBR3, and DPP4 and may merit
further investigation.
Heritability analysis revealed that miRNA Dage is a heritable trait
(h2 = 0.38). We did not, however, find genome-wide significant associ-
ations with miRNA Dage, likely due to an insufficient sample size for
GWAS of this trait.
We also showed that individuals with a predicted miRNA age greater
than their chronological age (i.e., higher miRNA Dage) exhibit higher
blood pressure and glucose levels, a higher prevalence of CHD and
hypertension, as well as increased risk of death from all causes. In
comparison, DNAm Dage was previously shown to be associated with
all-cause mortality, but not with prevalent CHD or hypertension (Marioni
et al., 2015; Horvath et al., 2016). mRNA Dage was reported to be
associated with blood pressure, glucose, and HDL and total cholesterol,
but not with all-cause mortality (Peters et al., 2015). In comparing
miRNA age with DNAm age and mRNA age in FHS Offspring
participants, miRNA age showed modest correlations with DNAm age
(r = 0.3) and mRNA age (r = 0.2), suggesting that miRNA age may
complement mRNA and epigenetic age prediction models and can
capture unique aspects of the molecular mechanisms of aging and age-
related diseases.
One limitation of this study is that we assessed miRNA expression in
whole blood, which consists of multiple cell types and plasma. To
address this, we tested whether the proportions of individual blood cell
types influenced the association of age with miRNA expression levels. In
comparing results with and without cell type adjustment, we observed
only minimal changes due to cell type composition. In our previous
miRNA expression QTL study, we also did not find substantial cell type
effects on the correlation between genetic variants and miRNA
expression. Another limitation is that we were unable to perform
external replication of our results. To our knowledge, no other study has
published extensive analyses of miRNA expression in relation to age in a
large sample size with a wide age range. In addition, by splitting our
sample set into independent discovery and replications sets, we
demonstrated a high degree of replicability of our age-related miRNAs.
Experimental procedures
Study population
The FHS Offspring cohort was initially recruited in 1971 and included
5124 offspring (and their spouses) from the FHS Original cohort. The FHS
Third Generation cohort was recruited from 2002 to 2005 and included
4095 adult children of the Offspring cohort participants (Feinleib et al.,
1975; Splansky et al., 2007). The samples used for miRNA analysis in the
present study (N = 5221) included 2295 participants from the FHS
Offspring cohort who attended the eighth examination cycle (Exam 8,
2005–2008) and 2926 participants from the FHS Third Generation
cohort who attended the second examination cycle (Exam 2, 2008–
2011). Because the samples from the Offspring and Third Generation
cohorts share familial relatedness, we merged the samples from the two
cohorts together. Next, the entire FHS sample set was split 1:1 by
pedigrees into separate discovery and replication sets. To ensure that the
samples in the discovery set did not share relatedness with samples in the
replication set, a given pedigree was assigned either to the discovery or
to the replication set, but not in both.
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Gene (mRNA) expression data were obtained from 2446 FHS
Offspring (Exam 8) and 3180 Third Generation (Exam 2) participants
(Huan et al., 2015a). DNA methylation data were obtained from 2377
FHS Offspring cohort participants (Exam 8). miRNA and mRNA expres-
sion data were available for 5012 participants, and there were 2079
participants with miRNA, mRNA, and DNA methylation data. All
participants provided written consent for genetic research.
miRNA expression profiling and normalization
Peripheral whole-blood samples were collected in PAXgene tubes
(Asuragen, Inc., Austin, TX, USA). Purified RNA was extracted using
the PAXgene Blood RNA System Kit (Qiagen, Venlo, Netherlands). The
WT-Ovation Pico RNA Amplification System (NuGEN, San Carlos, CA,
USA) was used to amplify 50 ng RNA samples according to the
manufacturer’s recommended protocols. RNA quality was measured
using an Agilent 2100 Bioanalyzer and RNA concentration was quan-
tified using a NanoDrop ND-1000 spectrophotometer. miRNA profiling
was carried out at the high-throughput Gene Expression and Biomarker
Core Laboratory at the University of Massachusetts Medical School using
TaqMan chemistry-based miRNA assays by using Dynamic Arrays on
BioMark System (Fluidigm, South San Francisco, CA, USA).
The initial miRNA list encompassed all TaqMan miRNA assays available
at the start of the study, including 754 miRNAs that were profiled in
~600 FHS individuals. 346 miRNAs expressed in > 20% samples were
further profiled in 2445 FHS Offspring and 3245 Third Generation cohort
participants. Quantification of miRNA expression was based on cycle
threshold (Ct), where lower Ct values signify higher miRNA expression
levels. miRNAs with Ct values ≥ 27 indicated that they were not
expressed in the sample. Outlier miRNAs with Ct values ≥ 5 standard
deviations from the mean Ct value were categorized as missing. We
excluded miRNAs expressed in < 5000 samples and samples with > 10%
of miRNAs having missing values from analysis. A total of 150 miRNAs
and 5221 samples remained for analysis, and 1.2% of remaining missing
values were replaced with Ct = 27.
As previously described, raw miRNA Ct values were adjusted for four
technical variables: isolation batch (50 batches), RNA concentration, RNA
quality (defined as RNA integrity number [RIN]), and RNA 260/280 ratio
(ratio of absorbance at 260 and 280 nm; measured using a spectropho-
tometer). This normalization model explained 20% to 60% of variability
of raw miRNA measurements for 80% of miRNAs.
mRNA expression profiling
Messenger RNA (mRNA) expression profiling of whole blood-derived
RNA was performed using the Affymetrix Human Exon 1.0 ST GeneChip
platform including 17 318 transcripts. Robust multichip average (RMA)
methods were used to normalize mRNA expression values (log-2-
transformed expression intensity) with quality control measures as
previously described (Joehanes et al., 2013).
DNA methylation
Buffy coat preparations were obtained from peripheral whole-blood
samples. Genomic DNA was extracted from buffy coat using the Gentra
Puregene DNA extraction kit (Qiagen, Venlo, Netherlands) and bisulfite-
converted using EZ DNA Methylation kit (Zymo Research, Irvine, CA,
USA). Samples underwent whole-genome amplification, fragmentation,
array hybridization, and single base pair extension. DNA methylation
quantification was conducted in two laboratory batches at the Johns
Hopkins Center for Inherited Disease Research (lab batch #1, N = 576)
and University of Minnesota Biomedical Genomics Center (lab batch #2,
N = 2270).
Methylation beta values were generated using the DASEN method-
ology implemented in the wateRmelon package in R version 3.0, which
includes background adjustment and quantile normalization. Sample
exclusion criteria included poor SNP matching of control positions,
missing rate > 1%, poor single nucleotide polymorphism (SNP) matching
to the 65 SNP control probe locations, outliers from multidimensional
scaling (MDS), and sex mismatch. Probes were excluded if missing rate
> 20%, previously identified to map to multiple locations, or having an
underlying SNP (minor allele frequency > 5% in European ancestry (EUR)
1000 Genomes Project data) at the CpG site or within 10 bp of the
single base extension. A total of 2377 samples and 443 252 CpG probes
remained for analysis.
Imputing cell counts
The cell count proportions of whole blood were measured in 2138 Third
Generation FHS participants (Exam 2), but not for all samples used in this
study. Cell counts were imputed using a partial least-squares regression
method (Abdi, 2010) applied to mRNA expression. The estimated cell
count proportion values imputed were generally consistent with the
measured values in the 2138 samples with cross-validated estimates of
prediction accuracy r2 > 0.8 for white blood cell, red blood cell, platelet,
lymphocyte percent, monocyte percent, and eosinophil percent, and
r2 = 0.25 for basophil percent. miRNA expression analysis accounting for
cell counts effects was performed in the 5012 samples.
Identifying differentially expressed miRNAs in relation to age
A linear mixed-effects model was used to model miRNA expression Ct
values (150 miRNAs in total) as the dependent variable and chronological
age as an explanatory variable, adjusting for sex, technical variables
(batch, RNA concentration, RNA quality score, and 260/280 ratio), and
family structure. In a sensitivity analysis, additional adjustments were
made for imputed cell counts. The statistical analysis was implemented in
the lmekin() R function (http://cran.r-project.org/web/packages/kinship/)
(Almasy & Blangero, 1998). Correcting for 150 tests (the number of
miRNAs), Bonferroni-corrected P < 3.3 9 104 was used as the signif-
icant threshold.
miRNA expression age prediction
The standardized residuals of miRNA expression Ct values (150 miRNAs)
were obtained by adjusting raw Ct values for three technical covariates
(RNA concentration, RNA quality score, and 260/280 ratio) and sex.
Because miRNA expression measurements for the FHS Offspring and
Third Generation cohorts were performed in independent batches, we
did not adjust Ct values for batch effect. In a sensitivity analysis,
additional adjustments were made for imputed cell counts.
We used an elastic net regression model (implemented in the R
package glmnet function (Friedman et al., 2010)) to regress chronolog-
ical age on miRNAs. Elastic net regression is a combination of traditional
Lasso and ridge regression methods, emphasizing model sparsity while
appropriately balancing the contributions of coexpressed miRNAs. To
ensure an unbiased validation, the prediction model was trained in the
discovery set. Optimal regularization parameters were estimated via 10-
fold cross-validation. The alpha parameter of glmnet was set to 0.5, and
the lambda value from the best prediction model was set to 0.2. glmnet
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automatically selected miRNAs for building an age predictor and
reported effect size for each miRNA. miRNA predicted age (i.e., miRNA
age) was calculated in the replication set using the predictor trained in
the discovery set. miRNA Dage was defined as miRNA age minus
chronological age.
Estimation of the additive heritability of miRNA Dage
The narrow-sense heritability estimate of miRNA Dage (denoted as
h2miRDage was the proportion of the additive polygenic genetic variance
of the total phenotypic variance of miRNA Dage:
h2miRDage ¼ r2A=r2miRDage, where r2A denotes the additive polygenic
genetic variance and r2miRDage denotes the total phenotypic variance of a
gene expression trait. The h2miRDage estimate was obtained using
variance-component methodology implemented in the lmekin() function
of Kinship Package in R (Almasy & Blangero, 1998). Heritability
estimation for miRNA Dage was performed using all FHS samples.
All-cause mortality ascertainment
Outcome analyses included all deaths that occurred prior to January 1,
2014 (about 6 years of follow-up). Survival status was ascertained using
multiple strategies, including routine contact with participants for health
history updates, surveillance at the local hospital, review of obituaries in
the local newspaper, and queries to the National Death Index. We
requested death certificates, hospital and nursing home records prior to
death, and autopsy reports. When cause of death was undeterminable,
the next of kin were interviewed. The date and cause of death were
reviewed by an endpoint panel of three investigators.
Associations between miRNA Dage and mortality were tested using
Cox proportional hazards regression models utilizing the coxph()
function in the ‘survival’ R library (https://stat.ethz.ch/R-manual/R-deve
l/library/survival/html/coxph.html), adjusting for age at sample collection
and sex. Potential cofounders that were included in the fully adjusted
model included systolic blood pressure, diastolic blood pressure, BMI,
HDL cholesterol, total cholesterol, triglycerides, fasting blood glucose,
smoking status, lipid treatment, diabetes treatment, hypertension
treatment, prevalent cardiovascular disease, prevalent cancer, and
prevalent diabetes. Hazard ratios for miRNA Dage were expressed as
annual risk of death over 6 years of follow-up. Survival curves were
drawn by tertiles of miRNA Dage.
Association analysis of miRNA Dage with prevalent CHD,
prevalent diabetes, prevalent hypertension, and
cardiometabolic traits
To avoid the cofounding effects of drug treatment, all association tests
of miRNA Dage and cardiometabolic traits were performed in individuals
who were not receiving antihypertensive, lipids, or diabetes treatment
(n = 2993). Linear mixed-effects models were used to test associations
between miRNA Dage (dependent variable) and cardiometabolic traits
(independent variable), including systolic blood pressure, diastolic blood
pressure, total cholesterol, HDL cholesterol, triglycerides, fasting blood
glucose, and BMI using the lmekin() R function. All association tests were
adjusted for chronological age, sex, and familial relatedness. To account
for the effects of obesity on cardiovascular disease and other traits, we
additionally adjusted for BMI (except in analyses of BMI).
Linear mixed-effects models (R package lmekin() function) were used
to test associations between miRNA Dage (dependent variable) and
prevalent CHD, diabetes, and hypertension (independent variable,
coding ‘1’ for cases and ‘0’ for controls), adjusting for age, sex, BMI,
and familial relatedness. Association analysis of miRNA Dage with CHD
was performed in all available samples (n = 5221, including 250
prevalent CHD cases). Diabetes and hypertension analyses were
performed in individuals who were not receiving antidiabetic treatment
(n = 4909, including 164 type-II diabetes cases) and antihypertensive
treatment (n = 3481, including 379 hypertension cases), respectively.
miRNA–mRNA coexpression analysis
The coexpression analysis was performed on FHS participants in whom
miRNA andmRNAdatawere both available. Linearmixed-effectsmodels (R
package lmekin() function) were used to conduct pairwise coexpression
analyses for all profiled mRNAs (N = 17 318) and 150 miRNAs, with fixed
effects includingage, sex, technical covariates, imputed cell types, surrogate
variables (SV), and a random effect to account for family structure. As
described above, the mRNA expression was quantified by log-2-
transformed expression intensities. For miRNA expression, higher Ct values
reflect lower miRNA expression levels. Adjustment was made for technical
covariates (11 for mRNA expression and four for miRNA expression).
Surrogate variables (SVs) were computed from the mRNA expression data
using theRpackage ‘SVA’ (Leek&Storey, 2007), and51SVs associatedwith
at least one miRNA at Bonferroni-corrected P < 3.3 9 104 (0.05/150)
were included in the statistical model. The Benjamini–Hochberg method
was used to compute false discovery rate (FDR). Significant miRNA–mRNA
coexpression pairs were selected using FDR < 0.05.
Predicting miRNA targets
For the coexpressed miRNA–mRNA pairs, we used TargetScan v7.0
(Lewis et al., 2005; Agarwal et al., 2015) to predict whether the mRNAs
were the corresponding targets for the miRNAs. TargetScan predicts
mRNA targets of miRNAs by searching for the presence of 8-mer, 7-mer,
and 6-mer sites that match the seed region of each miRNA. The
sequences from 30UTR, 50UTR, and coding regions of each mRNA were
downloaded from the University of California Santa Cruz (UCSC)
Table Browser (https://genome.ucsc.edu/). The miRNA seed regions
were downloaded from miRbase v21 (http://www.mirbase.org/).
Genome-wide association study of miRNA Dage
DNA was isolated from buffy coat or from immortalized lymphoblast cell
lines in FHS participants. Genotyping was conducted with the Affymetrix
500K mapping array and the Affymetrix 50K gene-focused MIP array,
using previously described quality control procedures (Levy et al., 2009).
Genotypes were imputed to the 1000 Genomes Project panel of
approximately 36.3 million variants using MACH (Li et al., 2010). We
filtered out SNPs with MAF < 0.05 and imputation quality ratio < 0.3
(the imputation quality ratio is denoted by the ratio of the variances of
the observed and the estimated allele counts). About 9 million variants
remained after the filter. The association of miRNA Dage with each SNP
was tested by a linear mixed-effects model that was implemented in the
lmekin() R function. miRNA Dage was used as dependent variable, and
each SNP as an explanatory variable adjusting for chronological age and
sex.
Gene ontology and pathway enrichment analysis
Coexpressed or predicted targeted mRNAs for age-associated miRNAs
were combined as gene sets and classified using Gene Ontology (GO)
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databases to identify potentially relevant biological processes. Fisher’s
exact test was used to calculate enrichment P values. DAVID Bioinfor-
matics resources 6.7 (https://david.ncifcrf.gov/) (Huang et al., 2009), an
online tool for GO analysis, was used for this analysis. The significant
threshold was set at FDR < 0.05.
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